Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinsuning Jiaonang
- Development stage
- Unknown
- Lead developer
- Shaanxi Momentum Pharmaceutical
- Administration
- Oral
01
Overview
Xinsuning Jiaonang (also known as Xin Su Ning) is a patented traditional Chinese medicine (TCM) capsule developed and manufactured by Shaanxi Momentum Pharmaceutical. It is formulated from 11 herbal ingredients, including Coptidis Rhizoma, Pinelliae Rhizoma, Poria, Aurantii Fructus Immaturus, Dichroae Radix, Nelumbinis Plumula, Sophorae Flavescentis Radix, Artemisiae Annuae Herba, Ginseng Radix, Ophiopogonis Radix, and Glycyrrhizae Radix. Xinsuning Jiaonang is approved in China for the treatment of cardiac arrhythmias, particularly premature ventricular contractions (PVCs) associated with phlegm-heat heart-disturbed syndrome, coronary heart disease, and viral myocarditis. It acts as a multi-channel blocker, exhibiting Class I and Class III antiarrhythmic properties by blocking cardiac sodium (hNav1.5) and potassium (hERG) channels, thereby prolonging action potential duration and increasing the effective refractory period of cardiac electrical conduction.
- Brand names
- XinsuningXinsuning CapsuleXinsuning Jiaonang
- Other names
- Xin Su NingXin-su-ningXSNXSN capsule
02
Targets
KCNH2 (Voltage-gated potassium channel subfamily H member 2)SCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on Xinsuning Jiaonang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xinsuning Jiaonang.